ReviewJournal of Crohn's & colitis2016
Preventing Collateral Damage in Crohn's Disease: The Lémann Index.
Review in Journal of Crohn's & colitis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Short Chain Fatty Acids Lower Inflammation and Restore Intestinal Integrity and Function Markers inNutrients · 2025Article
- Mesenteric fat proliferation on magnetic resonance enterography is a predictor of long-term disease complications in crohn's disease.BMC gastroenterology · 2025Article
- Role and mechanism of gut microbiota-host interactions in the pathogenesis of Crohn's disease.International journal of colorectal disease · 2025Review
- Magnetic resonance enterography for predicting poor prognosis in Crohn's disease: a systematic review with meta-analysis.Therapeutic advances in gastroenterology · 2025Review
- Integrating Gut Microbiome and Metabolomics with Magnetic Resonance Enterography to Advance Bowel Damage Prediction in Crohn's Disease.Journal of inflammation research · 2025Article
- Prospective Validation of the Lémann Index in Children: A Report From the Multicentre Image Kids Study.Journal of Crohn's & colitis · 2023Article
- Multi-omics in Crohn's disease: New insights from inside.Computational and structural biotechnology journal · 2023Review
- Gut microbiota analysis for prediction of clinical relapse in Crohn's disease.Scientific reports · 2022Observational
- Young age and shorter duration of Crohn's disease are associated with non-adherence to taking medication.Northern clinics of Istanbul · 2022Article
- Efficacy of early intervention on the bowel damage and intestinal surgery of Crohn's disease, based on the Lémann index.BMC gastroenterology · 2020Article
- Bowel Damage at Diagnosis Using the Lémann Index Score in Saudi Arabian Patients With Crohn's Disease.Cureus · 2020Article
- Crohn's disease.Nature reviews. Disease primers · 2020Review
- Earlier Anti-Tumor Necrosis Factor Therapy of Crohn's Disease Correlates with Slower Progression of Bowel Damage.Digestive diseases and sciences · 2019Article
- Timely Use of Biologics in Early Crohn's Disease: The Return of "Hit Hard and Early"?Digestive diseases and sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease [CD] is a chronic progressive and destructive condition. Half of all CD patients will develop bowel damage at 10 years. As in rheumatic diseases, preventing the organ damage consequent to CD complications [fistula, abscess, and/or stricture] is emerging as a new therapeutic goal for these patients in clinical practice. This might be the only way to alter disease course, as surgery is often required for disease complications. Similar to the joint damage in rheumatoid arthritis, bowel damage has also emerged as a new endpoint in disease-modification trials such as the REACT trial. Recently, the Lemann Index [LI] has been developed to measure CD-related bowel damage, and to assess damage progression over time, in order to evaluate the impact of therapeutic strategies in terms of preventing bowel damage. While validation is pending, recent reports suggested that bowel damage is reversible by anti-tumour necrosis factor [TNF] therapy. The Lémann index may play a key role in CD management, and should be implemented in all upcoming disease-modification trials in CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.